JAMA Intern Med

DoxyPEP reduces bacterial STIs in HIV PrEP users

January 9, 2025

Clinical impact: Doxycycline postexposure prophylaxis (doxyPEP) could be a valuable addition to STI prevention strategies for individuals at high risk of bacterial STIs, particularly those using HIV PrEP.

Study design: This retrospective cohort study included 11, 551 adults (≥18 years) who were assigned male sex at birth and either living with HIV or using HIV PrEP. They were instructed to take a 200-mg dose of doxycycline within 72 hours after sexual activity.

Results: DoxyPEP significantly reduced the incidence of chlamydia and syphilis among participants. However, the results for gonorrhea were mixed, with some reduction observed but not as pronounced as for the other STIs. Findings were consistent across different demographic groups within the study population.

Source:

Traeger MW, et al. (2025, January 6). JAMA Intern Med. Doxycycline Postexposure Prophylaxis and Bacterial Sexually Transmitted Infections Among Individuals Using HIV Preexposure Prophylaxis. https://pubmed.ncbi.nlm.nih.gov/39761062/